View Future GrowthBPH Global 과거 순이익 실적과거 기준 점검 0/6BPH Global은 연평균 15.5%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 13.3%의 비율로 증가했습니다. 매출은 연평균 64.6%의 비율로 감소했습니다.핵심 정보15.47%순이익 성장률34.09%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률-64.64%자기자본이익률n/a순이익률-124.84%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Oct 03Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.016 loss in FY 2023)Full year 2024 results: AU$0.006 loss per share (improved from AU$0.016 loss in FY 2023). Revenue: AU$110.0k (up AU$109.6k from FY 2023). Net loss: AU$1.98m (loss narrowed 49% from FY 2023).Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.018 loss in FY 2023)Full year 2024 results: AU$0.001 loss per share (improved from AU$0.018 loss in FY 2023). Revenue: AU$110.0k (up AU$109.6k from FY 2023). Net loss: AU$1.60m (loss narrowed 63% from FY 2023).Reported Earnings • Oct 05Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.005 loss in FY 2022)Full year 2023 results: AU$0.004 loss per share (improved from AU$0.005 loss in FY 2022). Net loss: AU$4.26m (loss narrowed 20% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in FY 2022)Full year 2023 results: AU$0.003 loss per share. Net loss: AU$3.75m (loss widened 1.7% from FY 2022).모든 업데이트 보기Recent updates공시 • Jun 22BPH Global Ltd Announces Board ChangesBPH Global Ltd. announced the resignation of its Chairman Mr. Paul Stephenson from the Board of Directors. Mr. Stephenson will continue to provide services to the Company as a contracted consultant under an ongoing consultancy arrangement. Current Executive Director, Mr. Francesco Cannavo, has now assumed the role of interim Executive Chairman.Board Change • May 20Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 3 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Non-Executive Chairman Paul Stephenson is the most experienced director on the board, commencing their role in 2020. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.공시 • Feb 13BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 1 million.BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 500,000,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Transaction Features: Subsequent Direct Listing공시 • Feb 05BPH Global Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million.BPH Global Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 500,000,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Transaction Features: Subsequent Direct Listing공시 • Sep 19BPH Global Ltd, Annual General Meeting, Nov 14, 2025BPH Global Ltd, Annual General Meeting, Nov 14, 2025.공시 • Sep 17BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.5501 million.BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.5501 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 250,000,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • May 02BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.609 million.BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.609 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 304,500,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Apr 28BPH Global Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.609 million.BPH Global Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.609 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 304,500,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Dec 31BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.125 million.BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.125 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,666,667 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Dec 17BPH Global Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.125 million.BPH Global Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.125 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,666,667 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct ListingReported Earnings • Oct 03Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.016 loss in FY 2023)Full year 2024 results: AU$0.006 loss per share (improved from AU$0.016 loss in FY 2023). Revenue: AU$110.0k (up AU$109.6k from FY 2023). Net loss: AU$1.98m (loss narrowed 49% from FY 2023).공시 • Oct 02BPH Global Ltd, Annual General Meeting, Nov 27, 2024BPH Global Ltd, Annual General Meeting, Nov 27, 2024.Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.018 loss in FY 2023)Full year 2024 results: AU$0.001 loss per share (improved from AU$0.018 loss in FY 2023). Revenue: AU$110.0k (up AU$109.6k from FY 2023). Net loss: AU$1.60m (loss narrowed 63% from FY 2023).New Risk • Jul 31New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.5m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-AU$244k). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€476.1k market cap, or US$515.7k).공시 • Apr 11BPH Global Ltd. Announces Executive ChangesBPH Global Limited announced the appointment of Justyn Stedwell as Company Secretary. Justyn has over 17 years' experience as a Company Secretary of ASX listed companies and has also served as a Non-Executive Director on several ASX listed company Boards. He holds a Bachelor of Commerce from Monash University, a Graduate Diploma of Accounting from Deakin University and Graduate Diploma in Applied Corporate Governance from the Governance Institute of Australia. Further to this appointment, Belinda Cleminson and Shelby Coleman have resigned as joint CompanySecretaries.공시 • Jan 18BPH Global Ltd Announces Change of Joint Company SecretaryBPH Global Ltd. announced that Shelby Coleman has been appointed as Joint Company Secretary, effective immediately. Ms Coleman holds a Bachelor of Laws and a Bachelor of Arts from Victoria University of Wellington.She is experienced in ASX and ASIC compliance, providing advice on corporate governance and compliance issues as well as other regulatory maters. As a member of Automic Group's Company Secretary team, Ms Coleman assists a number of ASX listed, unlisted public and proprietary companies across a range of industries. Further to this appointment, Ms Elizabeth Spooner will step down as Joint Company Secretary effecve immediately. Ms Belinda Cleminson of Automic Group will continue in her role, being Joint Company Secretary.New Risk • Dec 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m (AU$339 revenue, or US$231). Market cap is less than US$10m (€1.59m market cap, or US$1.75m).공시 • Dec 12BPH Global Ltd (ASX:BP8) completed the acquisition of Foshan Gedishi Biotechnology Co Ltd from two China Partners.BPH Global Ltd (ASX:BP8) entered into a legally binding terms sheet to acquire Foshan Gedishi Biotechnology Co Ltd from two China Partners for AUD 0.2 million on September 19, 2023. BPH Global Ltd (ASX:BP8) entered into an agreement to acquire Foshan Gedishi Biotechnology Co Ltd from two China Partners on September 20, 2023. BPH Global will issue 100 million shares as consideration. Completion of the transaction is subject to due diligence on Foshan, any requisite Australian regulatory, ASX, China regulatory approvals and shareholder approvals for the transaction being obtained by BPH and the two China Partners entering into Executive Employment Agreements with Foshan. Completion of the acquisition will take place by October 31, 2023. As of October 20, 2023, Completion of the acquisition is anticipated to occur 2 business days following the Company’s AGM on 21 November 2023 where shareholder approval for the issuance of shares to the vendors is being sought.BPH Global Ltd (ASX:BP8) completed the acquisition of Foshan Gedishi Biotechnology Co Ltd from two China Partners on December 11, 2023.공시 • Oct 20BPH Global Ltd, Annual General Meeting, Nov 21, 2023BPH Global Ltd, Annual General Meeting, Nov 21, 2023, at 16:00 AUS Eastern Standard Time. Location: at Automic offices at Suite 5, Level 12, 530 Collins Street, Melbourne VIC 3000 Melbourne Australia Agenda: To consider the Adoption of Remuneration Report; To consider the Election of Yanhua Huang as Director; To consider the Re-election of Huan Qing Gu as Director; To consider the ASX Listing Rule 7.1A Approval of Future Issue of Securities; To consider the Ratification of Prior Issue of Placement Shares; To consider the Approval of Issue of Placement Options; To consider the Approval of Issue of Options to Sanlam Private Wealth Pty Ltd; To consider the Approval of Issue of Shares and Options on conversion of 368,750 Convertible Notes; To consider the Approval of Issue of Shares and Options to Mr Paul Stephenson, Director of the Company; To consider the Approval of Issue of Shares and Options to Mr Francesco Cannavo, Director of the Company; To consider the Approval of Issue of Shares and Options to Mr Matthew Leonard, Director of the Company; and to consider other matters if any.Reported Earnings • Oct 05Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.005 loss in FY 2022)Full year 2023 results: AU$0.004 loss per share (improved from AU$0.005 loss in FY 2022). Net loss: AU$4.26m (loss narrowed 20% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.공시 • Sep 21BPH Global Ltd (ASX:BP8) entered into a legally binding terms sheet to acquire Foshan Gedishi Biotechnology Co Ltd from two China Partners for AUD 0.2 million.BPH Global Ltd (ASX:BP8) entered into a legally binding terms sheet to acquire Foshan Gedishi Biotechnology Co Ltd from two China Partners for AUD 0.2 million on September 19, 2023. BPH Global will issue 100 million shares as consideration. Completion of the transaction is subject to due diligence on Foshan, any requisite Australian regulatory, ASX, China regulatory approvals and shareholder approvals for the transaction being obtained by BPH and the two China Partners entering into Executive Employment Agreements with Foshan. Completion of the acquisition will take place by October 31, 2023.Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in FY 2022)Full year 2023 results: AU$0.003 loss per share. Net loss: AU$3.75m (loss widened 1.7% from FY 2022).New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.7m free cash flow). Share price has been highly volatile over the past 3 months (259% average daily change). Earnings have declined by 0.7% per year over the past 5 years. Market cap is less than US$10m (€1.56m market cap, or US$1.69m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).공시 • Jul 06BPH Global Ltd Appoints Michael Huang as Non-Executive DirectorThe Board of BPH Global Ltd. advised the appointment of Michael (Yanhua) Huang to the Board of Directors of the Company as a Non-Executive Director. Michael's return to the Board of BP8, marks a further consolidation of the Company' strategy to reinvigorate and further develop its bird's nest and dendrobium-infused bird's nest sales business in China (Bird's Nest Business). Michael Huang took the lead role on behalf of BP8 in conducting the pilot program in January and February this year. The pilot program trialled supply and distribution channels for the sale of bird's nest products via China Tobacco's outlets in Guangzhou and via social media influencers on Douyin, the China version of TikTok. Michael Huang brings his extensive experience and personal network in sales and marketing to the Board.공시 • May 12Stemcell United Limited Announces Board ChangesStemcell United Limited advised that Mr. Paul Rosen has tendered his resignation as a Non-Executive Director and Chairman, effective 12 May 2023.The Company announced the appointment of Mr. Paul Stephenson as independent non-executive Chair of the Board, effective immediately.Board Change • Apr 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Executive Director Matthew Leonard was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.매출 및 비용 세부 내역BPH Global가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:USZ0 매출, 비용 및 순이익 (AUD Millions)날짜매출순이익일반관리비연구개발비31 Dec 252-22030 Sep 251-22030 Jun 250-11031 Mar 250-11031 Dec 240-11030 Sep 240-21030 Jun 240-22031 Mar 240-22031 Dec 230-22030 Sep 230-32030 Jun 230-42031 Mar 230-53031 Dec 220-54030 Sep 220-54030 Jun 220-54031 Mar 223-54031 Dec 215-43030 Sep 217-33030 Jun 218-33031 Mar 216-23031 Dec 204-22030 Sep 202-22030 Jun 201-11031 Mar 201-21031 Dec 191-21030 Sep 191-22030 Jun 192-22031 Mar 191-22031 Dec 181-22030 Sep 181-32030 Jun 180-32031 Mar 180-52031 Dec 170-62030 Sep 170-51030 Jun 170-41031 Mar 170-191031 Dec 160-351030 Sep 160-351030 Jun 160-361031 Mar 160-181031 Dec 150-11030 Sep 1503710양질의 수익: USZ0 은(는) 현재 수익성이 없습니다.이익 마진 증가: USZ0는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: USZ0는 수익성이 없지만 지난 5년 동안 연평균 15.5%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 USZ0의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: USZ0은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(4.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: USZ0의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/30 17:52종가2026/06/30 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BPH Global Ltd는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Oct 03Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.016 loss in FY 2023)Full year 2024 results: AU$0.006 loss per share (improved from AU$0.016 loss in FY 2023). Revenue: AU$110.0k (up AU$109.6k from FY 2023). Net loss: AU$1.98m (loss narrowed 49% from FY 2023).
Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.018 loss in FY 2023)Full year 2024 results: AU$0.001 loss per share (improved from AU$0.018 loss in FY 2023). Revenue: AU$110.0k (up AU$109.6k from FY 2023). Net loss: AU$1.60m (loss narrowed 63% from FY 2023).
Reported Earnings • Oct 05Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.005 loss in FY 2022)Full year 2023 results: AU$0.004 loss per share (improved from AU$0.005 loss in FY 2022). Net loss: AU$4.26m (loss narrowed 20% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in FY 2022)Full year 2023 results: AU$0.003 loss per share. Net loss: AU$3.75m (loss widened 1.7% from FY 2022).
공시 • Jun 22BPH Global Ltd Announces Board ChangesBPH Global Ltd. announced the resignation of its Chairman Mr. Paul Stephenson from the Board of Directors. Mr. Stephenson will continue to provide services to the Company as a contracted consultant under an ongoing consultancy arrangement. Current Executive Director, Mr. Francesco Cannavo, has now assumed the role of interim Executive Chairman.
Board Change • May 20Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 3 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Non-Executive Chairman Paul Stephenson is the most experienced director on the board, commencing their role in 2020. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
공시 • Feb 13BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 1 million.BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 500,000,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Transaction Features: Subsequent Direct Listing
공시 • Feb 05BPH Global Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million.BPH Global Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 500,000,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Transaction Features: Subsequent Direct Listing
공시 • Sep 19BPH Global Ltd, Annual General Meeting, Nov 14, 2025BPH Global Ltd, Annual General Meeting, Nov 14, 2025.
공시 • Sep 17BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.5501 million.BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.5501 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 250,000,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • May 02BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.609 million.BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.609 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 304,500,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Apr 28BPH Global Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.609 million.BPH Global Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.609 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 304,500,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Dec 31BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.125 million.BPH Global Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.125 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,666,667 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Dec 17BPH Global Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.125 million.BPH Global Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.125 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,666,667 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
Reported Earnings • Oct 03Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.016 loss in FY 2023)Full year 2024 results: AU$0.006 loss per share (improved from AU$0.016 loss in FY 2023). Revenue: AU$110.0k (up AU$109.6k from FY 2023). Net loss: AU$1.98m (loss narrowed 49% from FY 2023).
공시 • Oct 02BPH Global Ltd, Annual General Meeting, Nov 27, 2024BPH Global Ltd, Annual General Meeting, Nov 27, 2024.
Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.018 loss in FY 2023)Full year 2024 results: AU$0.001 loss per share (improved from AU$0.018 loss in FY 2023). Revenue: AU$110.0k (up AU$109.6k from FY 2023). Net loss: AU$1.60m (loss narrowed 63% from FY 2023).
New Risk • Jul 31New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.5m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-AU$244k). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€476.1k market cap, or US$515.7k).
공시 • Apr 11BPH Global Ltd. Announces Executive ChangesBPH Global Limited announced the appointment of Justyn Stedwell as Company Secretary. Justyn has over 17 years' experience as a Company Secretary of ASX listed companies and has also served as a Non-Executive Director on several ASX listed company Boards. He holds a Bachelor of Commerce from Monash University, a Graduate Diploma of Accounting from Deakin University and Graduate Diploma in Applied Corporate Governance from the Governance Institute of Australia. Further to this appointment, Belinda Cleminson and Shelby Coleman have resigned as joint CompanySecretaries.
공시 • Jan 18BPH Global Ltd Announces Change of Joint Company SecretaryBPH Global Ltd. announced that Shelby Coleman has been appointed as Joint Company Secretary, effective immediately. Ms Coleman holds a Bachelor of Laws and a Bachelor of Arts from Victoria University of Wellington.She is experienced in ASX and ASIC compliance, providing advice on corporate governance and compliance issues as well as other regulatory maters. As a member of Automic Group's Company Secretary team, Ms Coleman assists a number of ASX listed, unlisted public and proprietary companies across a range of industries. Further to this appointment, Ms Elizabeth Spooner will step down as Joint Company Secretary effecve immediately. Ms Belinda Cleminson of Automic Group will continue in her role, being Joint Company Secretary.
New Risk • Dec 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m (AU$339 revenue, or US$231). Market cap is less than US$10m (€1.59m market cap, or US$1.75m).
공시 • Dec 12BPH Global Ltd (ASX:BP8) completed the acquisition of Foshan Gedishi Biotechnology Co Ltd from two China Partners.BPH Global Ltd (ASX:BP8) entered into a legally binding terms sheet to acquire Foshan Gedishi Biotechnology Co Ltd from two China Partners for AUD 0.2 million on September 19, 2023. BPH Global Ltd (ASX:BP8) entered into an agreement to acquire Foshan Gedishi Biotechnology Co Ltd from two China Partners on September 20, 2023. BPH Global will issue 100 million shares as consideration. Completion of the transaction is subject to due diligence on Foshan, any requisite Australian regulatory, ASX, China regulatory approvals and shareholder approvals for the transaction being obtained by BPH and the two China Partners entering into Executive Employment Agreements with Foshan. Completion of the acquisition will take place by October 31, 2023. As of October 20, 2023, Completion of the acquisition is anticipated to occur 2 business days following the Company’s AGM on 21 November 2023 where shareholder approval for the issuance of shares to the vendors is being sought.BPH Global Ltd (ASX:BP8) completed the acquisition of Foshan Gedishi Biotechnology Co Ltd from two China Partners on December 11, 2023.
공시 • Oct 20BPH Global Ltd, Annual General Meeting, Nov 21, 2023BPH Global Ltd, Annual General Meeting, Nov 21, 2023, at 16:00 AUS Eastern Standard Time. Location: at Automic offices at Suite 5, Level 12, 530 Collins Street, Melbourne VIC 3000 Melbourne Australia Agenda: To consider the Adoption of Remuneration Report; To consider the Election of Yanhua Huang as Director; To consider the Re-election of Huan Qing Gu as Director; To consider the ASX Listing Rule 7.1A Approval of Future Issue of Securities; To consider the Ratification of Prior Issue of Placement Shares; To consider the Approval of Issue of Placement Options; To consider the Approval of Issue of Options to Sanlam Private Wealth Pty Ltd; To consider the Approval of Issue of Shares and Options on conversion of 368,750 Convertible Notes; To consider the Approval of Issue of Shares and Options to Mr Paul Stephenson, Director of the Company; To consider the Approval of Issue of Shares and Options to Mr Francesco Cannavo, Director of the Company; To consider the Approval of Issue of Shares and Options to Mr Matthew Leonard, Director of the Company; and to consider other matters if any.
Reported Earnings • Oct 05Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.005 loss in FY 2022)Full year 2023 results: AU$0.004 loss per share (improved from AU$0.005 loss in FY 2022). Net loss: AU$4.26m (loss narrowed 20% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
공시 • Sep 21BPH Global Ltd (ASX:BP8) entered into a legally binding terms sheet to acquire Foshan Gedishi Biotechnology Co Ltd from two China Partners for AUD 0.2 million.BPH Global Ltd (ASX:BP8) entered into a legally binding terms sheet to acquire Foshan Gedishi Biotechnology Co Ltd from two China Partners for AUD 0.2 million on September 19, 2023. BPH Global will issue 100 million shares as consideration. Completion of the transaction is subject to due diligence on Foshan, any requisite Australian regulatory, ASX, China regulatory approvals and shareholder approvals for the transaction being obtained by BPH and the two China Partners entering into Executive Employment Agreements with Foshan. Completion of the acquisition will take place by October 31, 2023.
Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in FY 2022)Full year 2023 results: AU$0.003 loss per share. Net loss: AU$3.75m (loss widened 1.7% from FY 2022).
New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.7m free cash flow). Share price has been highly volatile over the past 3 months (259% average daily change). Earnings have declined by 0.7% per year over the past 5 years. Market cap is less than US$10m (€1.56m market cap, or US$1.69m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).
공시 • Jul 06BPH Global Ltd Appoints Michael Huang as Non-Executive DirectorThe Board of BPH Global Ltd. advised the appointment of Michael (Yanhua) Huang to the Board of Directors of the Company as a Non-Executive Director. Michael's return to the Board of BP8, marks a further consolidation of the Company' strategy to reinvigorate and further develop its bird's nest and dendrobium-infused bird's nest sales business in China (Bird's Nest Business). Michael Huang took the lead role on behalf of BP8 in conducting the pilot program in January and February this year. The pilot program trialled supply and distribution channels for the sale of bird's nest products via China Tobacco's outlets in Guangzhou and via social media influencers on Douyin, the China version of TikTok. Michael Huang brings his extensive experience and personal network in sales and marketing to the Board.
공시 • May 12Stemcell United Limited Announces Board ChangesStemcell United Limited advised that Mr. Paul Rosen has tendered his resignation as a Non-Executive Director and Chairman, effective 12 May 2023.The Company announced the appointment of Mr. Paul Stephenson as independent non-executive Chair of the Board, effective immediately.
Board Change • Apr 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Executive Director Matthew Leonard was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.